** Shares of Cibus CBUS.O down 30.5% premarket to $1.64 after agricultural biotechnology firm's follow-on prices
** CBUS shares set for fifth straight session of declines
** San Diego, California-based gene-editing co announces ~15.7 mln shares at $1.75 for $27.5 mln gross proceeds
** Offering price represents 25.8% discount to stock's last close
** Board chairman and co-founder Rory Riggs bought ~5.7 mln shares, or $10 mln worth of the offering
** Co says intends to use net offering proceeds to fund development of weed management productivity traits in rice and for working capital and other general purposes, as it pursues longer-term financing
** With ~34.4 mln shares outstanding, co has $81 mln market cap
** CBUS shares hit a record intraday low of $1.40 on Apr 7. Stock ended 2024 at $2.78 and was trading around $11 a year ago
** 3 of 4 analysts covering CBUS rate stock "buy" and 1 rates "hold"; PTs range from as low as $2 (Jefferies) to as high as $25 (H.C. Wainwright), latest LSEG data shows
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.